Published in Vaccine Weekly, April 5th, 2000
"The purpose of our efforts is to trigger the immune destruction of established cancer," W.W. Overwijk and colleagues, U.S. National Cancer Institute, Maryland. "Interleukin (IL)-2 can mediate the regression of tumors in patients with melanoma and renal cell carcinoma."
Overwijk et al. published the results of their study in the Cancer Journal from Scientific American ("The future of interleukin-2: Enhancing therapeutic anticancer vaccines," Cancer J Sci Am, 2000;6(Suppl. 1):S76-S80).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly